BriaCell Therapeutics Warrant Net Tangible Assets

BriaCell Therapeutics Warrant posts a net tangible assets of $23M as of April 2026. That compares with $12M in the prior-year period — up 96.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, BriaCell Therapeutics Warrant's net tangible assets was $12M. The latest reading is $23M — a 96.0% year-over-year increase (period ending April 2026). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of BriaCell Therapeutics Warrant's financial statement story. At $23M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BCTXZ's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BriaCell Therapeutics Warrant's other metric pages and overview cover the third.

Judging BriaCell Therapeutics Warrant against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in net tangible assets easier to interpret. Start with $23M here, then scan peer and history charts to see if the gap is persistent.